English
Segment disclosures
Company overviewCrinetics Pharmaceuticals, Inc.
Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.
Revenue · Reported segment facts
3 dimension combinations 31 retained observations 9 reported periods
Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.
License And Service · Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:LicenseAndServiceMember;us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 1080000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 1508000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 428000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 2276000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1031000 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1392000 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 361000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1039000 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4013000 | USD | 20260226 | Open filing evidence |
Product · Reportable Segment
Product Or Service · Statement Business Segments
Source dimensions
srt:ProductOrServiceAxis=us-gaap:ProductMember;us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 24038000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 34344000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 10306000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 5420000 | USD | 20260226 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 0 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 0 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 0 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 0 | USD | 20260226 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 0 | USD | 20260226 | Open filing evidence |
Reportable Segment
Statement Business Segments
Source dimensions
us-gaap:StatementBusinessSegmentsAxis=crnx:ReportableSegmentMember| Period | Value | Unit | Filed | Evidence |
|---|---|---|---|---|
| 2026-04-01 – 2026-06-30 | 25118000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-06-30 | 35852000 | USD | 20260803 | Open filing evidence |
| 2026-01-01 – 2026-03-31 | 10734000 | USD | 20260507 | Open filing evidence |
| 2025-01-01 – 2025-12-31 | 7696000 | USD | 20260226 | Open filing evidence |
| 2025-07-01 – 2025-09-30 | 143000 | USD | 20251106 | Open filing evidence |
| 2025-01-01 – 2025-09-30 | 1535000 | USD | 20251106 | Open filing evidence |
| 2025-04-01 – 2025-06-30 | 1031000 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-06-30 | 1392000 | USD | 20260803 | Open filing evidence |
| 2025-01-01 – 2025-03-31 | 361000 | USD | 20260507 | Open filing evidence |
| 2024-01-01 – 2024-12-31 | 1039000 | USD | 20260226 | Open filing evidence |
| 2024-07-01 – 2024-09-30 | 0 | USD | 20251106 | Open filing evidence |
| 2024-01-01 – 2024-09-30 | 1039000 | USD | 20251106 | Open filing evidence |
| 2023-01-01 – 2023-12-31 | 4013000 | USD | 20260226 | Open filing evidence |